FDA — authorised 26 June 1986
- Marketing authorisation holder: HOSPIRA
- Status: approved
🇺🇸 Cupric Chloride In Plastic Container in United States
FDA authorised Cupric Chloride In Plastic Container on 26 June 1986
Marketing authorisations
FDA — authorised 26 June 1986
- Application: NDA018960
- Marketing authorisation holder: HOSPIRA
- Local brand name: CUPRIC CHLORIDE IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 31 October 2022
- Application: ANDA212071
- Marketing authorisation holder: EXELA PHARMA
- Local brand name: CUPRIC CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 April 2024
- Application: ANDA216113
- Marketing authorisation holder: SOMERSET
- Local brand name: CUPRIC CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 April 2024
- Application: ANDA217626
- Marketing authorisation holder: STIRA
- Local brand name: CUPRIC CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 26 January 2026
- Application: ANDA217287
- Marketing authorisation holder: AMNEAL
- Local brand name: CUPRIC CHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
Cupric Chloride In Plastic Container in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in United States
Frequently asked questions
Is Cupric Chloride In Plastic Container approved in United States?
Yes. FDA authorised it on 26 June 1986; FDA authorised it on 26 June 1986; FDA authorised it on 31 October 2022.
Who is the marketing authorisation holder for Cupric Chloride In Plastic Container in United States?
HOSPIRA holds the US marketing authorisation.